Abstract

Myotonic Dystrophy Type 1 (MD1) is an autosomal dominant neurological condition. It affects multiple systems and organs leading to physical and at time mental disabilities. Although there is no current definitive cure for MD1, several available therapeutic interventions could be implemented to improve the prognosis and quality of life of patients with MD1. This article will review MD1’s etiology, multisystem involvement and its therapeutic modalities.